Log in

NASDAQ:EDSA - Edesa Biotech Stock Price, Forecast & News

-0.03 (-0.83 %)
(As of 02/24/2020 07:48 AM ET)
Today's Range
Now: $3.60
50-Day Range
MA: $3.38
52-Week Range
Now: $3.60
Volume30,351 shs
Average Volume40,082 shs
Market Capitalization$31.90 million
P/E RatioN/A
Dividend YieldN/A
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the development and advancement of treatments for dermatological and gastrointestinal indications. Its lead product candidate is EB01, a non-steroidal anti-inflammatory molecule to treat chronic allergic contact dermatitis. The company was founded in 2015 and is headquartered in Markham, Canada.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:EDSA



Sales & Book Value

Annual Sales$210,000.00
Book Value$12.69 per share


Net Income$-5,030,000.00
Net Margins-784.77%


Market Cap$31.90 million
Next Earnings Date5/13/2020 (Estimated)
OptionableNot Optionable

Receive EDSA News and Ratings via Email

Sign-up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter.

Edesa Biotech (NASDAQ:EDSA) Frequently Asked Questions

What is Edesa Biotech's stock symbol?

Edesa Biotech trades on the NASDAQ under the ticker symbol "EDSA."

How were Edesa Biotech's earnings last quarter?

Edesa Biotech (NASDAQ:EDSA) released its quarterly earnings data on Thursday, December, 12th. The company reported ($0.07) earnings per share for the quarter. The firm earned $0.41 million during the quarter. Edesa Biotech had a negative net margin of 784.77% and a negative return on equity of 80.11%. View Edesa Biotech's Earnings History.

When is Edesa Biotech's next earnings date?

Edesa Biotech is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for Edesa Biotech.

Has Edesa Biotech been receiving favorable news coverage?

News headlines about EDSA stock have been trending very negative on Monday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Edesa Biotech earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Edesa Biotech.

Are investors shorting Edesa Biotech?

Edesa Biotech saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 23,200 shares, an increase of 28.2% from the December 31st total of 18,100 shares. Based on an average trading volume of 38,100 shares, the short-interest ratio is presently 0.6 days. Currently, 0.8% of the company's shares are short sold. View Edesa Biotech's Current Options Chain.

Who are some of Edesa Biotech's key competitors?

What other stocks do shareholders of Edesa Biotech own?

Who are Edesa Biotech's key executives?

Edesa Biotech's management team includes the folowing people:
  • Dr. Pardeep Nijhawan FRCPC, M.D., CEO & Director (Age 48)
  • Dr. Michael J. Brooks M.B.A., Ph.D., Pres (Age 41)
  • Ms. Kathi Niffenegger CPA, CPA, Chief Financial Officer (Age 62)

Who are Edesa Biotech's major shareholders?

Edesa Biotech's stock is owned by many different of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.33%). Company insiders that own Edesa Biotech stock include Der Velden Peter Van, Frank R Oakes and Michael J Brooks. View Institutional Ownership Trends for Edesa Biotech.

Which major investors are buying Edesa Biotech stock?

EDSA stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Edesa Biotech stock in the last two years include Der Velden Peter Van and Michael J Brooks. View Insider Buying and Selling for Edesa Biotech.

How do I buy shares of Edesa Biotech?

Shares of EDSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Edesa Biotech's stock price today?

One share of EDSA stock can currently be purchased for approximately $3.60.

How big of a company is Edesa Biotech?

Edesa Biotech has a market capitalization of $31.90 million and generates $210,000.00 in revenue each year. Edesa Biotech employs 6 workers across the globe.View Additional Information About Edesa Biotech.

What is Edesa Biotech's official website?

The official website for Edesa Biotech is http://www.edesabiotech.com/.

How can I contact Edesa Biotech?

Edesa Biotech's mailing address is 100 SPY COURT, MARKHAM A6, L3R 5H6. The company can be reached via phone at 905-475-1234 or via email at [email protected]

MarketBeat Community Rating for Edesa Biotech (NASDAQ EDSA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  11 (Vote Outperform)
Underperform Votes:  13 (Vote Underperform)
Total Votes:  24
MarketBeat's community ratings are surveys of what our community members think about Edesa Biotech and other stocks. Vote "Outperform" if you believe EDSA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDSA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Featured Article: Inverted Yield Curve

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel